title: Rapid response to a college outbreak of meningococcal serogroup B disease: Nation's first widespread use of bivalent rLP2086 vaccine.
abstract: OBJECTIVE
  To outline the reasoning behind use of bivalent rLP2086 in a Rhode Island college meningococcal B disease outbreak, highlighting the timeline from outbreak declaration to vaccination clinic, emphasizing that these two time points are <3 days apart.
  
  
  METHODS
  Staff, faculty, and students at College X eligible for vaccination.
  
  
  METHODS
  An outbreak response was initiated, advantages/disadvantages of available MenB vaccines were discussed, and a vaccination clinic was coordinated.
  
  
  RESULTS
  Bivalent rLP2086 was chosen as the vaccination intervention. We achieved a 94% coverage rate for the first dose. To date, this intervention has prevented further cases of Neisseria meningitidis serogroup B disease at College X.
  
  
  CONCLUSIONS
  The close, efficient collaboration of public health stakeholders and College X led 94% of the eligible population to be safely vaccinated with at least one dose of bivalent rLP2086. This outbreak marked the first time bivalent rLP2086 was effectively used as an intervention response.
authors.affiliation: a Department of Pediatric Infectious Diseases , Hasbro Children's Hospital, The Warren Alpert Medical School of Brown University , Providence , Rhode Island , USA.
authors.forename: Theresa M
authors.initials: TM
authors.lastname: Fiorito
authors.affiliation: b Student Health Center, Providence College , Providence , Rhode Island , USA.
authors.forename: Suzanne
authors.initials: S
authors.lastname: Bornschein
authors.affiliation: c Rhode Island Department of Health , Center for Emergency Preparedness and Response , Providence , Rhode Island , USA.
authors.forename: Alysia
authors.initials: A
authors.lastname: Mihalakos
authors.affiliation: b Student Health Center, Providence College , Providence , Rhode Island , USA.
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Kelleher
authors.affiliation: d Rhode Island Department of Health , The Warren Alpert Medical School of Brown University , Providence , Rhode Island , USA.
authors.forename: Nicole
authors.initials: N
authors.lastname: Alexander-Scott
authors.affiliation: e Emergency Management, Providence College , Providence , Rhode Island , USA.
authors.forename: Koren V
authors.initials: KV
authors.lastname: Kanadanian
authors.affiliation: c Rhode Island Department of Health , Center for Emergency Preparedness and Response , Providence , Rhode Island , USA.
authors.forename: Patricia
authors.initials: P
authors.lastname: Raymond
authors.affiliation: b Student Health Center, Providence College , Providence , Rhode Island , USA.
authors.forename: Kenneth
authors.initials: K
authors.lastname: Sicard
authors.affiliation: a Department of Pediatric Infectious Diseases , Hasbro Children's Hospital, The Warren Alpert Medical School of Brown University , Providence , Rhode Island , USA.
authors.forename: Penelope H
authors.initials: PH
authors.lastname: Dennehy
mesh_terms: D000942:Antigens, Bacterial / Q000494:pharmacology / Q000627:therapeutic use; D001426:Bacterial Proteins / Q000494:pharmacology / Q000627:therapeutic use; D002959:Civil Defense / Q000379:methods / Q000458:organization & administration*; D004196:Disease Outbreaks; D005178:Faculty / Q000706:statistics & numerical data; D006801:Humans; D008589:Meningococcal Infections / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology; D022401:Meningococcal Vaccines / Q000494:pharmacology / Q000627:therapeutic use*; D038541:Neisseria meningitidis, Serogroup B / Q000472:pathogenicity; D011634:Public Health / Q000379:methods / Q000639:trends; D012237:Rhode Island / Q000453:epidemiology; D013334:Students / Q000706:statistics & numerical data; D014495:Universities / Q000706:statistics & numerical data / Q000639:trends*
chemical_list: D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D022401:Meningococcal Vaccines; C484699:factor H-binding protein, Neisseria meningitidis
keywords: Bivalent rLP2086; Neisseria meningitidis; meningococcal B disease; vaccination